Jeffrey B. Landau - Jul 19, 2022 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
Chief Business Officer
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Jeffrey B Landau
Stock symbol
CTMX
Transactions as of
Jul 19, 2022
Transactions value $
-$5,982
Form type
4
Date filed
7/21/2022, 04:11 PM
Previous filing
Mar 28, 2022
Next filing
Aug 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Award $0 +11.3K +47.51% $0.00 34.9K Jul 19, 2022 Direct F1, F2, F3
transaction CTMX Common Stock Sale -$5.98K -4.21K -12.04% $1.42 30.7K Jul 20, 2022 Direct F2, F4
holding CTMX Common Stock 4.5K Jul 19, 2022 Fidelity Traditional IRA
holding CTMX Common Stock 3.18K Jul 19, 2022 Schwab ROTH IRA
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The first milestone vesting condition was determined to be satisfied upon which 50% of the PSUs vested.
F2 Includes 16,274 restricted stock units.
F3 Reflects the adjusted total which includes the purchase of 5,040 shares under the Cytomx Therapeutics Employee Stock Purchase Plan on May 31, 2022.
F4 The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSU of the Issuer.